<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: bioerodible drug delivery system", fill: "#a9203e"},
{source: "3: bioerodible drug delivery system", target: "3: early stage", fill: "#a9203e"},
{source: "3: early stage", target: "3: development", fill: "#a9203e"},
{source: "3: bioerodible drug delivery system", target: "4: bioerodible drug delivery systems", fill: "#d70a53"},
{source: "4: bioerodible drug delivery systems", target: "4: through clinical trials", fill: "#d70a53"},
{source: "4: through clinical trials", target: "4: success with", fill: "#d70a53"},
{source: "4: success with", target: "4: development efforts", fill: "#d70a53"},
{source: "4: development efforts", target: "4: appropriate therapeutic compounds", fill: "#d70a53"},
{source: "4: appropriate therapeutic compounds", target: "4: regulatory approval", fill: "#d70a53"},
{source: "4: bioerodible drug delivery systems", target: "6: potential products", fill: "#0f0"},
{source: "6: potential products", target: "6: manufactured", fill: "#0f0"},
{source: "6: manufactured", target: "6: commercial quantities at", fill: "#0f0"},
{source: "6: potential products", target: "11: future capital requirements will depend on", fill: "#6f00ff"},
{source: "11: future capital requirements will depend on", target: "11: development programs", fill: "#6f00ff"},
{source: "11: development programs", target: "11: strategic collaborations", fill: "#6f00ff"},
{source: "11: strategic collaborations", target: "11: partnerships", fill: "#6f00ff"},
{source: "11: partnerships", target: "11: research development clinical testing manufacturing", fill: "#6f00ff"},
{source: "11: research development clinical testing manufacturing", target: "11: with preclinical", fill: "#6f00ff"},
{source: "11: with preclinical", target: "11: clinical trials", fill: "#6f00ff"},
{source: "11: clinical trials", target: "11: costs involved", fill: "#6f00ff"},
{source: "11: costs involved", target: "11: regulatory approvals", fill: "#6f00ff"},
{source: "11: regulatory approvals", target: "11: filing prosecuting", fill: "#6f00ff"},
{source: "11: filing prosecuting", target: "11: enforcing patent", fill: "#6f00ff"},
{source: "11: future capital requirements will depend on", target: "13: additional", fill: "#65000b"},
{source: "13: additional", target: "13: arrangements", fill: "#65000b"},
{source: "13: arrangements", target: "13: collaborative", fill: "#65000b"},
{source: "13: collaborative", target: "13: relinquish", fill: "#65000b"},
{source: "13: relinquish", target: "13: technologies", fill: "#65000b"},
{source: "13: technologies", target: "13: candidates", fill: "#65000b"},
{source: "13: candidates", target: "13: commercialize", fill: "#65000b"},
{source: "13: additional", target: "17: foreseeable future will rely upon outside", fill: "#ff007f"},
{source: "17: foreseeable future will rely upon outside", target: "17: contractors", fill: "#ff007f"},
{source: "17: contractors", target: "17: manufacture supply", fill: "#ff007f"},
{source: "17: manufacture supply", target: "17: us key intermediates", fill: "#ff007f"},
{source: "17: us key intermediates", target: "17: active pharmaceutical ingredients", fill: "#ff007f"},
{source: "17: active pharmaceutical ingredients", target: "17: formulated drug product", fill: "#ff007f"},
{source: "17: formulated drug product", target: "17: candidates", fill: "#ff007f"},
{source: "17: foreseeable future will rely upon outside", target: "21: local governments", fill: "#c8a2c8"},
{source: "21: local governments", target: "21: United States ", fill: "#c8a2c8"},
{source: "21: United States ", target: "21: significant", fill: "#c8a2c8"},
{source: "21: significant", target: "21: regulations", fill: "#c8a2c8"},
{source: "21: regulations", target: "21: activities", fill: "#c8a2c8"},
{source: "21: local governments", target: "22: preclinical testing", fill: "#ffe4e1"},
{source: "22: preclinical testing", target: "22: clinical trials", fill: "#ffe4e1"},
{source: "22: clinical trials", target: "22: collaborators", fill: "#ffe4e1"},
{source: "22: collaborators", target: "22: government regulation", fill: "#ffe4e1"},
{source: "22: government regulation", target: "22: may prevent us from", fill: "#ffe4e1"},
{source: "22: may prevent us from", target: "22: commercially viable", fill: "#ffe4e1"},
{source: "22: commercially viable", target: "22: products from", fill: "#ffe4e1"},
{source: "22: products from", target: "22: discoveries", fill: "#ffe4e1"},
{source: "22: preclinical testing", target: "48: competition potentially", fill: "#aa98a9"},
{source: "48: competition potentially", target: "48: pharmaceutical", fill: "#aa98a9"},
{source: "48: pharmaceutical", target: "48: drug delivery companies", fill: "#aa98a9"},
{source: "48: competition potentially", target: "START_HERE", fill: "#aa98a9"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Industrial Materials</td>
    </tr>
    <tr>
      <td>Construction Materials</td>
    </tr>
    <tr>
      <td>Materials</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Starlink">Starlink</a></td>
      <td>Starlings are small to medium-sized passerine birds in the family Sturnidae. The name "Sturnidae" comes from the Latin word for starling, sturnus.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tecovirimat">Tecovirimat</a></td>
      <td>Tecovirimat, sold under the brand name Tpoxx among others, is an antiviral medication with activity against orthopoxviruses such as smallpox and monkeypox. It is the first antipoxviral drug approved in the United States.The drug works by blocking cellular transmission of the virus, thus preventing the disease.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Praziquantel">Praziquantel</a></td>
      <td>Praziquantel (PZQ), sold under the brandname Biltricide among others, is a medication used to treat a number of types of parasitic worm infections in mammals, birds, amphibians, reptiles, and fish. In humans specifically, it is used to treat schistosomiasis, clonorchiasis, opisthorchiasis, tapeworm infections, cysticercosis, hydatid disease, and other fluke infections.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Merger_of_Sprint_Corporation_and_T-Mobile_US">Merger of Sprint Corporation and T-Mobile US</a></td>
      <td>Sprint Corporation and T-Mobile US merged in 2020 in an all shares deal for $26 billion. The deal was announced on April 29, 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/1,2-Cyclohexane_dicarboxylic_acid_diisononyl_ester">1,2-Cyclohexane dicarboxylic acid diisononyl ester</a></td>
      <td>1,2-Cyclohexane dicarboxylic acid diisononyl ester (DINCH) is a mixture of organic compounds with the formula C6H10(CO2C9H19)2. DINCH is colorless oil.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Denosumab">Denosumab</a></td>
      <td>Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is contraindicated in people with low blood calcium levels. The most common side effects are joint and muscle pain in the arms or legs.Denosumab is a inhibitor of RANKL (receptor activator of nuclear factor kappa-Β ligand), which works by preventing the development of osteoclasts, which are cells that break down bone.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_Trials_Directive">Clinical Trials Directive</a></td>
      <td>The Clinical Trials Directive (Officially Directive 2001/20/EC of 4 April 2001, of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use) is a European Union directive that aimed at facilitating the internal market in medicinal products within the European Union, while at the same time maintaining an appropriate level of protection for public health. It seeks to simplify and harmonise the administrative provisions governing clinical trials in the European Community, by establishing a clear, transparent procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Controlled_clinical_trials">Controlled clinical trials</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Agilent_Technologies">Agilent Technologies</a></td>
      <td>Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sun_Pharma">Sun Pharma</a></td>
      <td>Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs)  in more than 100 countries across the globe. It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world, with a total revenue of over US$4.5 billion as of June 2021.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Central_Intelligence_Agency">Central Intelligence Agency</a></td>
      <td>The Central Intelligence Agency (CIA ), known informally as the Agency and historically as the Company, is a civilian foreign intelligence service of the federal government of the United States, officially tasked with gathering, processing, and analyzing national security information from around the world, primarily through the use of human intelligence (HUMINT) and performing covert actions. As a principal member of the United States Intelligence Community (IC), the CIA reports to the Director of National Intelligence and is primarily focused on providing intelligence for the President and Cabinet of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_sexual_activity">Human sexual activity</a></td>
      <td>Human sexual activity, human sexual practice or human sexual behaviour is the manner in which humans experience and express their sexuality. People engage in a variety of sexual acts, ranging from activities done alone (e.g., masturbation) to acts with another person (e.g., sexual intercourse, non-penetrative sex, oral sex, etc.) in varying patterns of frequency, for a wide variety of reasons.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/No_Activity">No Activity</a></td>
      <td>No Activity is an Australian comedy television series which streams on Stan. The series is about two detectives on a stakeout.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pursuit_of_Nazi_collaborators">Pursuit of Nazi collaborators</a></td>
      <td>The pursuit of Nazi collaborators refers to the post-World War II pursuit and apprehension of individuals who were not citizens of the Third Reich at the outbreak of World War II but collaborated with the Nazi regime during the war. Hence, this article does not cover former members of the NSDAP and their fates after the war.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bleiburg_repatriations">Bleiburg repatriations</a></td>
      <td>In May 1945, after the end of World War II in Europe, during which Yugoslavia had been occupied by the Axis powers, tens of thousands of soldiers and civilians associated with the Axis powers fled Yugoslavia to Austria as the Soviet Union (Red Army) and Yugoslav Partisans took control. When they reached Allied-occupied Austria, the British refused to accept their surrender and directed them to the Partisans instead despite knowing that they would be killed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutics">Pharmaceutics</a></td>
      <td>Pharmaceutics is the discipline of pharmacy that deals with the process of turning a new chemical entity (NCE) or old drugs into a medication to be used safely and effectively by patients.  It is also called the science of dosage form design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacy">Pharmacy</a></td>
      <td>Pharmacy is the clinical health science that links medical science with chemistry and it is charged with the discovery, production, disposal, safe and effective use, and control of medications and drugs. The practice of pharmacy requires excellent knowledge of drugs, their mechanism of action, side effects, interactions, mobility and toxicity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_code">Pharmaceutical code</a></td>
      <td>Pharmaceutical codes are used in medical classification to uniquely identify medication. They may uniquely identify an active ingredient, drug system (including inactive ingredients and time-release agents) in general, or a specific pharmaceutical product from a specific manufacturer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>AP PHARMA INC /DE/    ITEM 1A  Risk Factors    Item 1A  Risk Factors    RISK FACTORS  - ------------    Our business is subject to <font color="blue">various risks</font>, including those described below</td>
    </tr>
    <tr>
      <td>You <font color="blue">should carefully</font> consider these risk factors, together with all of the  other information included in this Form 10-K  Any of these risks could  <font color="blue">materially</font> <font color="blue">adversely</font> affect our business, operating results and financial  condition</td>
    </tr>
    <tr>
      <td>OUR BIOERODIBLE DRUG DELIVERY SYSTEM BUSINESS IS AT AN EARLY STAGE OF  DEVELOPMENT    Our <font color="blue">bioerodible <font color="blue">drug delivery system</font></font> business is at an <font color="blue">early stage</font> of  <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our ability to produce <font color="blue">bioerodible <font color="blue">drug delivery system</font></font>s that  progress to and <font color="blue">through <font color="blue">clinical trials</font></font> is subject to, among other things:     - <font color="blue">success with</font> our research and <font color="blue">development</font> efforts;     - selection of <font color="blue">appropriate therapeutic compounds</font> for delivery;     - the required <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td><font color="blue">Successful </font><font color="blue">development</font> of <font color="blue">delivery systems will</font> require <font color="blue">significant</font>  preclinical and <font color="blue"><font color="blue">clinical testing</font> prior</font> to <font color="blue"><font color="blue">regulatory</font> approval</font> in the United  States and elsewhere</td>
    </tr>
    <tr>
      <td>In addition, we will need to determine whether any  <font color="blue">potential products</font> can be <font color="blue"><font color="blue">manufacture</font>d</font> in <font color="blue">commercial quantities at</font> an  acceptable cost</td>
    </tr>
    <tr>
      <td>Our <font color="blue">efforts may</font> not result in a product that can be  marketed</td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">significant</font> scientific, <font color="blue">regulatory</font> and commercial  <font color="blue">milestones</font> that must be reached for any of our <font color="blue">research programs</font> to be  successful, any <font color="blue">program may</font> be abandoned, even after <font color="blue">significant</font> resources  have <font color="blue">been expended</font></td>
    </tr>
    <tr>
      <td>WE WILL NEED ADDITIONAL CAPITAL TO CONDUCT OUR OPERATIONS AND TO DEVELOP OUR  PRODUCTS AND OUR ABILITY TO OBTAIN THE NECESSARY FUNDING ON FAVORABLE TERMS  IN THE FUTURE IS UNCERTAIN    We will require <font color="blue"><font color="blue">additional</font> <font color="blue">capital resources</font></font> in order to conduct our  <font color="blue">operations</font> and develop our products</td>
    </tr>
    <tr>
      <td>While we estimate that our existing  <font color="blue">capital resources</font> and <font color="blue">interest income will</font> be sufficient to fund our current  level of <font color="blue">operations</font> for at least the <font color="blue">next year based on current</font> business  plans, we <font color="blue">cannot guarantee</font> that this will be the case</td>
    </tr>
    <tr>
      <td>The timing and degree  of any <font color="blue">future capital <font color="blue">requirement</font>s will depend on</font> many factors, including:     - scientific progress in our research and <font color="blue">development</font> programs;     - the magnitude and scope of our research and <font color="blue">development</font> programs;     - our ability to establish and maintain <font color="blue">strategic <font color="blue"><font color="blue">collaboration</font>s</font></font> or  <font color="blue">partnerships</font> for research, <font color="blue">development</font>, <font color="blue">clinical testing</font>, <font color="blue">manufacturing</font> and  marketing;     - our progress <font color="blue">with preclinical</font> and <font color="blue">clinical trials</font>;     - the time and <font color="blue">costs involved</font> in obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s;     - the <font color="blue">costs involved</font> in preparing, filing, prosecuting, maintaining,  defending and <font color="blue">enforcing patent</font> claims</td>
    </tr>
    <tr>
      <td>We intend to acquire <font color="blue">additional</font> funding through <font color="blue">strategic <font color="blue"><font color="blue">collaboration</font>s</font></font>, in  the form of license fees, research and <font color="blue">development</font> fees and milestone  payments</td>
    </tr>
    <tr>
      <td>In the event that <font color="blue">additional</font> funds are obtained through  <font color="blue">arrangements</font> with <font color="blue">collaborative</font> partners, these <font color="blue">arrangements</font> may require us  to <font color="blue">relinquish</font> rights to some of our <font color="blue">technologies</font>, product <font color="blue">candidates</font> or  products that we would otherwise seek to develop and <font color="blue">commercialize</font> ourselves</td>
    </tr>
    <tr>
      <td>If <font color="blue">sufficient funding</font> is not available, we may be required to delay, reduce  the scope of or <font color="blue">eliminate one</font> or more of our research or <font color="blue">development</font>  programs, each of <font color="blue">which could</font> have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>IF WE ARE UNABLE TO RECRUIT AND RETAIN SKILLED EMPLOYEES, WE MAY NOT BE ABLE  TO ACHIEVE OUR OBJECTIVES    Retaining our <font color="blue">current employees</font> and <font color="blue">recruiting qualified <font color="blue">scientific personnel</font></font>  to perform <font color="blue">future research</font> and <font color="blue">development</font> work will be critical to our  success</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>is intense for experienced <font color="blue">scientists</font>, and we may not  be able to recruit or retain <font color="blue">sufficient skilled personnel</font> to allow us to  <font color="blue">pursue <font color="blue"><font color="blue">collaboration</font>s</font></font> and develop our products and core <font color="blue">technologies</font> to the  <font color="blue">extent otherwise possible</font></td>
    </tr>
    <tr>
      <td>WE ARE RELIANT ON SINGLE SOURCE THIRD PARTY CONTRACTORS FOR THE MANUFACTURE  AND PRODUCTION OF RAW MATERIALS AND PRODUCT CANDIDATES    We currently, and for the foreseeable future will, rely upon outside  <font color="blue">contractors</font> to <font color="blue">manufacture</font>, supply and package for <font color="blue">us key intermediates</font>,  <font color="blue">active <font color="blue">pharmaceutical</font> ingredients</font> and <font color="blue">formulated drug product</font> for our product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">current <font color="blue">dependence upon</font> others</font> for the <font color="blue">manufacture</font> of our  <font color="blue">raw materials</font> and product <font color="blue">candidates</font> and our anticipated <font color="blue">dependence upon</font>  others for the <font color="blue">manufacture</font> of any products that we may develop, may <font color="blue">adversely</font>  affect our ability to develop our product <font color="blue">candidates</font> in a timely manner and  may <font color="blue">adversely</font> affect future profit margins and our ability to <font color="blue">commercialize</font>  any products that we may develop on a timely and <font color="blue">competitive basis</font></td>
    </tr>
    <tr>
      <td>ENTRY INTO CLINICAL TRIALS WITH ONE OR MORE PRODUCTS MAY NOT RESULT IN ANY  COMMERCIALLY VIABLE PRODUCTS    We do not expect to generate any <font color="blue">significant</font> revenues from product sales for  a period of <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>We may never <font color="blue">generate revenues</font> from product sales  or become profitable because of a variety of risks inherent in our business,  including risks that:     - we may be <font color="blue">unsuccessful</font> in <font color="blue">finding partners willing</font> to fund some or all of  our <font color="blue">clinical trial <font color="blue">expenditure</font>s</font>;     - <font color="blue">clinical trials</font> may not <font color="blue">demonstrate</font> the safety and efficacy of our  products;     - <font color="blue">completion</font> of <font color="blue">clinical trials</font> may be delayed, or costs of <font color="blue">clinical trials</font>  may exceed anticipated amounts;     - we may not be able to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> of our products, or may  experience delays in obtaining <font color="blue">such approvals</font>;     - we and our <font color="blue">licensees may</font> not be able to <font color="blue">successfully market</font> our products</td>
    </tr>
    <tr>
      <td>BECAUSE WE OR OUR COLLABORATORS MUST OBTAIN REGULATORY APPROVAL TO MARKET OUR  PRODUCTS IN THE UNITED STATES AND FOREIGN JURISDICTIONS, WE CANNOT PREDICT  WHETHER OR WHEN WE WILL BE PERMITTED TO COMMERCIALIZE OUR PRODUCTS    Federal, state and <font color="blue">local governments</font> in the <font color="blue">United States </font>and governments in  other countries have <font color="blue">significant</font> <font color="blue">regulations</font> in place that govern many of our  <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">pre<font color="blue">clinical testing</font></font> and <font color="blue">clinical trials</font> of the products that  we develop ourselves or that our <font color="blue">collaborators</font> develop are subject to  <font color="blue">government regulation</font> and <font color="blue">may prevent us from</font> creating <font color="blue"><font color="blue">commercially</font> viable</font>  <font color="blue">products from</font> our <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">sale by us</font> or our  <font color="blue">collaborators</font> of any <font color="blue"><font color="blue">commercially</font> viable</font> product will be subject to  <font color="blue">government regulation</font> from several standpoints, including the processes of:     - <font color="blue">manufacturing</font>;    - - labeling;     - <font color="blue">distributing</font>;     - <font color="blue">advertising</font> and promoting; and     - selling and marketing</td>
    </tr>
    <tr>
      <td>We may not obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for the products we develop and our  <font color="blue">collaborators</font> may not obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for the products they  develop</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">approval may also entail limitations on</font> the indicated  uses of a <font color="blue">proposed product</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> process, <font color="blue">particularly</font> for <font color="blue">bio<font color="blue">pharmaceutical</font> products</font> like  ours, is uncertain, can take many years and requires the <font color="blue">expenditure</font> of  substantial resources</td>
    </tr>
    <tr>
      <td>Any product that we or our <font color="blue">collaborative</font> partners  develop must receive all <font color="blue">relevant <font color="blue"><font color="blue">regulatory</font> agency approval</font>s</font> or <font color="blue">clearances</font>,  if any, before it may be marketed in the <font color="blue">United States </font>or other countries</td>
    </tr>
    <tr>
      <td>In particular, human <font color="blue">pharmaceutical</font> therapeutic products are subject to  <font color="blue">rigorous preclinical</font> and <font color="blue">clinical testing</font> and other <font color="blue"><font color="blue">requirement</font>s by</font> the Food  and Drug Administration in the <font color="blue">United States </font>and similar health <font color="blue">authorities</font>  in foreign countries</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> process, which includes extensive  <font color="blue">pre<font color="blue">clinical testing</font></font> and <font color="blue">clinical trials</font> of <font color="blue">each product</font> in order to establish  its safety and efficacy, is uncertain, can take many years and requires the  <font color="blue">expenditure</font> of substantial resources</td>
    </tr>
    <tr>
      <td>Data obtained <font color="blue">from preclinical</font> and clinical <font color="blue">activities</font> is susceptible to  <font color="blue">varying interpretations</font> that could delay, limit or <font color="blue">prevent <font color="blue">regulatory</font> agency</font>  approvals or <font color="blue">clearances</font></td>
    </tr>
    <tr>
      <td>In addition, delays or <font color="blue">rejections may</font> be  <font color="blue">encountered as</font> a result of changes in <font color="blue"><font color="blue">regulatory</font> agency policy during</font> the  period of product <font color="blue">development</font> and/or the period of review of any <font color="blue">application</font>  for <font color="blue"><font color="blue">regulatory</font> agency approval</font> or clearance for a product</td>
    </tr>
    <tr>
      <td>Delays in  obtaining <font color="blue"><font color="blue">regulatory</font> agency approval</font>s or <font color="blue">clearances</font> could:     - <font color="blue">significant</font>ly harm the marketing of any products that we or our  <font color="blue">collaborators</font> develop;     - <font color="blue">impose costly procedures upon</font> our <font color="blue">activities</font> or the <font color="blue">activities</font> of our  <font color="blue">collaborators</font>;     - diminish any <font color="blue">competitive advantages</font> that we or our <font color="blue">collaborative</font> partners  may attain; or     - <font color="blue">adversely</font> affect our ability to receive royalties and <font color="blue">generate revenues</font>  and profits</td>
    </tr>
    <tr>
      <td>In addition, the marketing and <font color="blue">manufacturing</font> of drugs and <font color="blue">biological products</font>  are subject to continuing FDA review, and <font color="blue">later discovery</font> of <font color="blue">previously</font>  <font color="blue">unknown problems with</font> a product, its <font color="blue">manufacture</font> or its <font color="blue">marketing may</font> result  in the FDA requiring <font color="blue">further clinical research</font> or <font color="blue">restrictions on</font> the product  or the <font color="blue">manufacture</font>r, including withdrawal of the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>WE DEPEND ON OUR COLLABORATORS TO HELP US COMPLETE THE PROCESS OF DEVELOPING  AND TESTING OUR PRODUCTS AND OUR ABILITY TO DEVELOP AND COMMERCIALIZE  PRODUCTS MAY BE IMPAIRED OR DELAYED IF OUR COLLABORATIVE PARTNERSHIPS ARE  UNSUCCESSFUL    Our strategy for the <font color="blue">development</font>, <font color="blue">clinical testing</font> and <font color="blue">commercialization</font> of  our products requires <font color="blue">entering into <font color="blue"><font color="blue">collaboration</font>s</font> with corporate partners</font>,  licensors, licensees and others</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent upon</font> the subsequent  success of these other parties in performing their respective  <font color="blue">responsibilities</font> and the <font color="blue">cooperation</font> of our partners</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> may  not <font color="blue">cooperate with us</font> or perform their <font color="blue">obligations under</font> our <font color="blue">agreements with</font>  them</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot control</font> the amount and timing of our <font color="blue">collaborators</font> &amp;apos   resources that will be devoted to our research <font color="blue">activities</font> related to our  <font color="blue">collaborative</font> <font color="blue">agreements with</font> them</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> may choose to pursue  existing or alternative <font color="blue">technologies</font> in preference to those being developed  in <font color="blue"><font color="blue">collaboration</font> with us</font></td>
    </tr>
    <tr>
      <td>Under <font color="blue">agreements with</font> <font color="blue">collaborators</font>, we may rely <font color="blue">significant</font>ly on them, among  other <font color="blue">activities</font>, to:     - <font color="blue">fund research</font> and <font color="blue">development</font> <font color="blue">activities</font> with us;     - <font color="blue">pay us fees upon</font> the <font color="blue">achievement</font> of <font color="blue">milestones</font>; and     - <font color="blue">market with us</font> any <font color="blue">commercial products</font> that result from our  <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>OUR RELIANCE ON THE RESEARCH ACTIVITIES OF OUR NON-EMPLOYEE SCIENTIFIC  ADVISORS AND OTHER RESEARCH INSTITUTIONS, WHOSE ACTIVITIES ARE NOT WHOLLY  WITHIN OUR CONTROL, MAY LEAD TO DELAYS IN TECHNOLOGICAL DEVELOPMENTS    We have <font color="blue">relationships with <font color="blue">scientific advisors</font> at academic</font> and other  <font color="blue">institutions</font>, some of <font color="blue">whom conduct research at</font> our request</td>
    </tr>
    <tr>
      <td>These scientific  advisors are not our employees and may have <font color="blue">commitments</font> to, or consulting or  <font color="blue">advisory contracts with</font>, other entities that may limit their <font color="blue">availability</font> to  us</td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">control over</font> the <font color="blue">activities</font> of these advisors and,  <font color="blue">except as otherwise</font> required by our <font color="blue">collaboration</font> and <font color="blue">consulting agreements</font>,  can expect only limited amounts of their time to be dedicated to our  <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">scientific advisors</font> are unable or refuse to contribute to  the <font color="blue">development</font> of any of our potential <font color="blue">discoveries</font>, our ability to generate  <font color="blue">significant</font> advances in our <font color="blue">technologies</font> will be <font color="blue">significant</font>ly harmed</td>
    </tr>
    <tr>
      <td>THE LOSS OF KEY PERSONNEL COULD SLOW OUR ABILITY TO CONDUCT RESEARCH AND  DEVELOP PRODUCTS    Our <font color="blue">future success depends</font> to a <font color="blue">significant</font> extent on the skills, experience  and efforts of our <font color="blue">executive officers</font> and key members of our scientific  staff</td>
    </tr>
    <tr>
      <td>We may be unable to retain our <font color="blue">current personnel</font> or attract or  assimilate other <font color="blue">highly qualified management</font> and <font color="blue">scientific personnel</font> in the  future</td>
    </tr>
    <tr>
      <td>The loss of any or all of these <font color="blue">individuals could harm</font> our business  and might <font color="blue">significant</font>ly delay or prevent the <font color="blue">achievement</font> of research,  <font color="blue">development</font> or business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>WE FACE INTENSE COMPETITION FROM OTHER COMPANIES    Most or all of the products we could develop or <font color="blue">commercialize</font> will face  <font color="blue">competition</font> from different therapeutic agents intended for treatment of the  <font color="blue">same indications</font> or from other <font color="blue">products <font color="blue">incorporating</font> drug delivery</font>  <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">competition</font> potentially</font> includes all of the <font color="blue">pharmaceutical</font>  and <font color="blue">drug delivery companies</font> in the world</td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">pharmaceutical</font>  companies have more financial resources, technical staff and <font color="blue">manufacturing</font>  and marketing <font color="blue">capabilities</font> than we do</td>
    </tr>
    <tr>
      <td>To the extent that we develop or  market products <font color="blue">incorporating</font> drugs that are off-patent, or are being  developed by multiple companies, we will face <font color="blue">competition</font> from other  companies developing and marketing similar products</td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical </font>companies are increasingly using <font color="blue">advertising</font>, including  direct-to-consumer <font color="blue">advertising</font>, in marketing their products</td>
    </tr>
    <tr>
      <td>The costs of  such <font color="blue">advertising</font> are very high and are increasing</td>
    </tr>
    <tr>
      <td>It may be <font color="blue">difficult</font> for  our Company to <font color="blue">compete with</font> larger companies investing greater resources in  these marketing <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue">pharmaceutical</font> companies are <font color="blue">aggressively seeking</font> to obtain new  <font color="blue">products by licensing products</font> or <font color="blue"><font color="blue">technology</font> from</font> other companies</td>
    </tr>
    <tr>
      <td>We will  be competing to license or acquire products or <font color="blue"><font color="blue">technology</font> with companies with</font>  far <font color="blue">greater financial</font> and other resources</td>
    </tr>
    <tr>
      <td>INABILITY TO OBTAIN SPECIAL MATERIALS COULD SLOW DOWN OUR RESEARCH AND  DEVELOPMENT PROCESS    Some of the <font color="blue">critical materials</font> and <font color="blue"><font color="blue">components</font> used</font> in our developed products  are <font color="blue">sourced from</font> a <font color="blue">single supplier</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">interruption</font> in supply of a key  material could <font color="blue">significant</font>ly delay our research and <font color="blue">development</font> process</td>
    </tr>
    <tr>
      <td>Special <font color="blue">materials must often</font> be <font color="blue"><font color="blue">manufacture</font>d</font> for the first time for use in  <font color="blue"><font color="blue">drug delivery system</font>s</font>, or <font color="blue">materials may</font> be used in the systems in a manner  <font color="blue">different from</font> their <font color="blue">customary commercial uses</font></td>
    </tr>
    <tr>
      <td>The quality of materials can  be critical to the performance of a <font color="blue">drug delivery system</font>, so a reliable  source of a <font color="blue">consistent supply</font> of materials is important</td>
    </tr>
    <tr>
      <td><font color="blue">Materials </font>or  <font color="blue">components</font> needed for our <font color="blue"><font color="blue">drug delivery system</font>s</font> may be <font color="blue">difficult</font> to obtain on  <font color="blue">commercially</font> reasonable terms, <font color="blue">particularly</font> when <font color="blue">relatively</font> small quantities  are required, or if the materials <font color="blue">traditionally</font> have not been used in  <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>PATENTS AND OTHER INTELLECTUAL PROPERTY PROTECTION MAY BE DIFFICULT TO OBTAIN  OR INEFFECTIVE    Patent <font color="blue">protection generally</font> has <font color="blue">been important</font> in the <font color="blue">pharmaceutical</font>  industry</td>
    </tr>
    <tr>
      <td>Our <font color="blue">existing <font color="blue">patents may</font></font> not cover future products, <font color="blue">additional</font>  <font color="blue">patents may</font> not be issued, and <font color="blue">current patents</font> or <font color="blue">patents issued</font> in the  <font color="blue">future may</font> not <font color="blue">provide meaningful protection</font> or prove to be of commercial  benefit</td>
    </tr>
    <tr>
      <td>In the United States, patents are granted for <font color="blue">specified periods</font> of time</td>
    </tr>
    <tr>
      <td>Other <font color="blue">companies may successfully challenge</font> our patents in the future</td>
    </tr>
    <tr>
      <td>Others  <font color="blue">may also challenge</font> the validity or <font color="blue">enforceability</font> of our patents in  <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>In addition, if  other companies are able to obtain patents that cover any of our <font color="blue">technologies</font>  or products, we may be subject to <font color="blue">liability</font> for damages and our <font color="blue">activities</font>  could be <font color="blue">blocked by legal action unless</font> we can obtain licenses to those  patents</td>
    </tr>
    <tr>
      <td>In addition, we utilize <font color="blue">significant</font> unpatented proprietary <font color="blue">technology</font> and  <font color="blue">rely on unpatented trade secrets</font> and proprietary know-how to <font color="blue">protect certain</font>  aspects of our products and <font color="blue">technologies</font> and the <font color="blue">methods used</font> to <font color="blue">manufacture</font>  them</td>
    </tr>
    <tr>
      <td>Other companies have or may develop similar <font color="blue">technology</font> which will  <font color="blue">compete with</font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>IF WE FAIL TO CONTINUE TO MEET THE NASDAQ NATIONAL MARKET &amp;apos S REQUIREMENTS FOR  CONTINUED LISTING, THE NASDAQ NATIONAL MARKET MAY DELIST OUR COMMON STOCK,  WHICH WOULD NEGATIVELY IMPACT THE PRICE OF OUR COMMON STOCK AND OUR ABILITY  TO SELL OUR COMMON STOCK    Our <font color="blue">common stock</font> is listed on the <font color="blue">Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td>The rules of the  <font color="blue">Nasdaq National Market</font> provide that issuers with <font color="blue">stockholders</font> &amp;apos  equity of less  than dlra10 million may be <font color="blue">delisted from</font> the <font color="blue">Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td>As of the  end of the <font color="blue">third fiscal quarter</font> of 2005, we failed to meet that <font color="blue">requirement</font>,  though we <font color="blue">regained compliance with</font> the <font color="blue">requirement</font> in January 2006</td>
    </tr>
    <tr>
      <td>In the  event that we fail to comply with all listing standards applicable to issuers  listed on the Nasdaq Stock Market, our <font color="blue">common stock</font> may be <font color="blue">delisted from</font> the  <font color="blue">Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td>In that event, we may be required to list our common  stock on the <font color="blue">Nasdaq Capital Market</font> provided we meet the listing <font color="blue">requirement</font>s  for the <font color="blue">Nasdaq Capital Market</font></td>
    </tr>
    <tr>
      <td>If we are delisted or required to list our  <font color="blue">common stock</font> on a market or <font color="blue">exchange less liquid than</font> the Nasdaq National  Market, it would be far more <font color="blue">difficult</font> for our <font color="blue">stockholders</font> to trade in our  securities and it may be more <font color="blue">difficult</font> to obtain accurate, current  information <font color="blue">concerning market prices</font> for our securities</td>
    </tr>
    <tr>
      <td>The <font color="blue">possibility</font>  that our <font color="blue">securities may</font> be delisted may also <font color="blue">adversely</font> affect our ability to  raise <font color="blue">additional</font> financing</td>
    </tr>
  </tbody>
</table>